WFH NETWORK

Laboratory sciences: Replacement therapy and testing | Virtual Summit 2020

 
Details

Year: 2020

Language: English

Author(s): World Federation of Hemophilia

View Online
Additional Information

In this session from the WFH 2020 Virtual Summit, Steve Kitchen, Emmanuel Favaloro, Robert Gosselin and Geoffrey Kershaw discuss:

  • How the emergence of chromogenic factor VIII testing has illuminated both discrepancies between testing methods and potential issues associated with product potency assessment
  • How the creation of B-domain deleted recombinant factor VIII replacement product has initiated the first real challenge for clinical laboratories to accurately monitor the advances in hemophilia replacement therapy
  • How the clinical laboratory may not possess the ideal laboratory test(s) for monitoring these new-age therapies, and it may be that a single F8 testing platform may not be adequate
  • A description of the EHL products and the optimal or acceptable laboratory F8 testing platforms

 

The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.

The WFH does not promote any particular pharmaceutical product and any mention of any commercial brand in this presentation is strictly for educational purposes.